Why the study?
Does low-molecular-weight heparin reduce all-cause mortality compared to unfractionated heparin in patients with acute pulmonary embolism requiring thrombolysis?
Population
249 patients with acute pulmonary embolism who required thrombolysis, mean age 60.7 ± 15.5 years.
Comparison
Low-molecular-weight heparin after thrombolytic… vs Unfractionated heparin after thrombolytic…
Design
Cohort
Follow-up
30 days
Authors
Loading...
LMWH associated with lower mortality after PE thrombolysis; leaves open need for RCTs before practice change.
Does low-molecular-weight heparin reduce all-cause mortality compared to unfractionated heparin in patients with acute pulmonary embolism requiring thrombolysis?
LMWH after thrombolysis for severe pulmonary embolism is associated with lower 30-day all-cause mortality and fewer bleeding events compared to the traditionally preferred UFH.
Şentürk et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: